scispace - formally typeset
M

Marco Bolis

Researcher at Mario Negri Institute for Pharmacological Research

Publications -  46
Citations -  791

Marco Bolis is an academic researcher from Mario Negri Institute for Pharmacological Research. The author has contributed to research in topics: Medicine & Retinoic acid. The author has an hindex of 13, co-authored 32 publications receiving 548 citations. Previous affiliations of Marco Bolis include Swiss Institute of Bioinformatics & University of Lugano.

Papers
More filters
Journal ArticleDOI

Retinoids and breast cancer: from basic studies to the clinic and back again.

TL;DR: The basic knowledge acquired on the anti-tumor activity of classic retinoids, like ATRA, in mammary tumors, is reviewed, focusing on the underlying cellular and molecular mechanisms and the determinants of retinoid sensitivity/resistance.
Journal ArticleDOI

Structure and evolution of vertebrate aldehyde oxidases: from gene duplication to gene suppression

TL;DR: This work cloned the cDNAs encoding the AOX proteins of guinea pig and cynomolgus monkeys, two unique species as to the evolution of this enzyme family, and identifies chimeric RNAs from the human AOX3 and AOx3L1 pseudogenes with potential to encode a novel microRNA.
Journal ArticleDOI

Cellular and molecular determinants of all-trans retinoic acid sensitivity in breast cancer: Luminal phenotype and RARα expression.

TL;DR: Gen sets of predictive potential which are associated with ATRA sensitivity in breast cancer cell lines are defined and validated in short‐term tissue cultures of Luminal/ER+ and triple‐negative tumors and perturbations in the transcriptomic profiles afforded by ATRA are determined.
Journal ArticleDOI

BET proteins regulate homologous recombination-mediated DNA repair: BRCAness and implications for cancer therapy.

TL;DR: The aim of this study was to assess BRD4 regulation in homologous recombination‐mediated DNA repair and to explore novel clinical strategies through the combinations of the pharmacological induction of epigenetic BRCAness in BRC a1 wild‐type triple negative breast cancer cells by means of BET inhibitors and compounds already available in clinic.